Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Sarcoma 1Ovarian Neoplasms 1Neoplasm Metastasis 1Melanoma 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 62Nivolumab 40Ipilimumab 24trametinib 13dabrafenib 10Specimen Handling 10Magnetic Resonance Spectroscopy 10binimetinib 9Cyclophosphamide 8CTLA-4 Antigen 8Biopsy 8encorafenib 7fludarabine 6Radiosurgery 6Cisplatin 6relatlimab 5cemiplimab 5atezolizumab 5Pemetrexed 5Introns 5Interleukin-2 5tislelizumab 4lenvatinib 4fludarabine phosphate 4durvalumab 4dostarlimab 4cobimetinib 4avelumab 4Radiotherapy 4Paclitaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Melanoma × aflibercept × Clear all
NCT02298959 2026-05-13

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
59 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicSarcoma

Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡